{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 9 of 122', '6', 'INVESTIGATIONAL PRODUCT INFORMATION', '40', '6.1 General Information', '40', '6.2 AR101 Product Characteristics', '41', '6.2.1 Packaging of AR101', '41', '6.2.2 Storage of AR101', '41', '6.2.3 Directions for Administration of AR101', '41', '6.3 Treatment Compliance', '43', '7', 'PRIOR AND CONCOMITANT THERAPY', '43', '7.1 Prior Medications', '43', '7.2 Concomitant Medications', '43', '7.3 Rescue Medications', '44', '7.4 Prohibited Medications', '44', '8', 'SAFETY CONSIDERATIONS', '45', '8.1 Safety Monitoring', '45', '8.2 Adverse Event Definitions', '45', '8.3 Assessment of Causal Relationship', '47', '8.4 Assessment of Severity (Intensity)', '48', '8.5 Special Safety Considerations', '50', '8.5.1 Assessment of Allergic Reactions', '50', '8.5.1.1 Assessment of Anaphylaxis', '50', '8.5.1.2 Assessment of the Tolerability of a Study Product Dose or Dose Level', '51', '8.5.2 Treatment of Allergic Reactions', '53', '8.5.3 Dose Adjustment of Study Product for Allergic Reactions', '54', '8.5.3.1 Dose Adjustment of Study Product During Initial Dose Escalation (Days 1 and 2)', '54', '8.5.3.2 Dose Adjustment of Study Product During Up-Dosing and Maintenance', '55', '8.5.4 Dose Adjustment of Study Product for Reasons Other Than Allergic Reactions to Study', 'Product', '60', '8.5.5 Missed Doses During Up-Dosing and Maintenance', '61', '8.5.6 Adverse Events of Interest', '62', '8.5.6.1 Anaphylaxis', '62', '8.5.6.2 GI Adverse Events Including Those of Interest', '62', '8.5.6.3 Accidental and Nonaccidental Food Allergen Exposure', '63', '8.5.6.4 Adverse Events With Severe Symptoms', '64', '8.5.6.5 Adverse Events Requiring Use of Epinephrine', '64', '8.5.7 Other Notable Events', '64', '8.5.7.1 Overdose', '64', '8.5.7.2 Pregnancy and Other Reproductive Considerations', '64', '8.6 Adverse Event Reporting', '65', '8.6.1 Adverse Event Reporting Period', '66', '8.6.2 Reporting for Serious Adverse Events, Adverse Events of Interest, and Other Notable', 'Events', '67', '8.6.2.1 Serious Adverse Events Reporting', '67', '8.6.2.2 Adverse Events of Interest Reporting', '68', '8.6.2.3 Other Notable Events Reporting', '68', '9', 'ASSESSMENT OF HRQOL, EFFICACY, AND SAFETY', '69', '9.1 Assessments of HRQOL and Other Subject- and Parent/Caregiver-Reported Outcomes', '69', '9.1.1 FAQLQ-PF, FAQLQ-PFT, and FAIM Questionnaires', '71', '9.1.2 FAQLQ-CF/FAIM-CF and FAQLQ-TF/FAIM-TF Questionnaires', '71']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 10 of 122', '9.1.3 FAQL-PB Questionnaire', '72', '9.1.4', 'HADS Questionnaire', '72', '9.1.5 EQ-5D Questionnaires', '72', '9.1.6 Assessments of Control and Confidence', '72', '9.1.7 Global Assessments of HRQOL', '73', '9.1.8 Assessments of Food Challenge Outcomes', '73', '9.1.9 TSQM-9 Questionnaire', '73', '9.1.10 Exit Questionnaire', '73', '9.1.11 Qualitative Exit Interview', '73', '9.2 Measures of Desensitization', '74', '9.2.1 Skin Prick Test', '74', '9.2.2 Open-Label Food Challenge', '74', '9.2.3 Real-World Peanut Challenge', '74', '9.3', 'Safety and Other Assessments', '74', '9.3.1 Lung Function Tests and Assessments of Asthma Control', '74', '9.3.2 TNSS Questionnaires', '77', '9.3.3', 'SCORAD Index', '77', '9.3.4 PEESS v2.0 Questionnaire', '77', '9.3.5 Physical Examinations and Vital Signs', '77', '10 STATISTICAL METHODS', '78', '10.1 Statistical and Analytical Plans', '78', '10.2 Analysis Populations', '78', '10.3 Determination of Sample Size', '79', '10.4 Interim Analyses', '79', '10.5 Analyses of HRQOL', '79', '10.6 Analysis of Other Questionnaires', '81', '10.7 Analysis of Efficacy', '81', '10.8 Analysis of Safety', '82', '10.9 Other Analyses', '83', '11 STUDY COMMITTEES AND COMMUNICATIONS', '84', '12 LABORATORY REQUIREMENTS', '84', '12.1 Clinical Laboratory Tests', '84', '12.2 Basophil Activation Test', '85', '13 INVESTIGATOR AND ADMINISTRATIVE REQUIREMENTS', '85', '13.1 Ethics', '85', '13.1.1 Ethics Committee', '85', '13.1.2 Ethical Conduct of the Study', '86', '13.1.3 Subject Information and Informed Consent and Assent', '86', '13.1.4 Maintaining Subject Confidentiality', '86', '13.2 Data Quality Assurance', '86', '13.2.1 Data Management', '86', '13.2.2 Case Report Forms', '87', '13.2.3 Study Monitoring', '87', '13.2.4 Study Audits', '87', '13.3 Investigational Product Accountability', '88', '13.4 Retention of Records', '89', '13.5 Protocol Deviations', '89']\n\n###\n\n", "completion": "END"}